Recent Company News

• 07:04 AM ET Sep 05, 2025
  

  RedHill Biopharma reports H1 gross profit $2.5M vs year-ago $1.2M ($1.23, 0.00)

• 07:00 AM ET Sep 05, 2025
  

  RedHill Biopharma Announces First Half 2025 Financial Results and Operational Highlights

• 09:27 AM ET Aug 20, 2025
  

  RedHill Biopharma Awarded $1.8 Million in Legal Costs and Expenses by New York Supreme Court in Addition to its Prior $8.25 Million Summary Judgment Win

• 09:03 AM ET Aug 20, 2025
  

  RedHill Biopharma awarded $1.8M in legal costs and expenses by New York Supreme Court in addition to prior $8.25M summary Judgment win ($1.45, 0.00)

• 09:02 AM ET Aug 19, 2025
  

  Jaguar Health family company Napo Pharmaceuticals to meet with FDA to discuss potential regulatory pathways for crofelemer for treatment of ultrarare pediatric indication microvillus inclusion disease (MVID) ($2.07, 0.00)

• 09:04 AM ET Aug 18, 2025
  

  RedHill Biopharma received Talicia licensing payments totaling $1.1M ($1.36, 0.00)

• 09:01 AM ET Aug 18, 2025
  

  RedHill Received Talicia® Licensing Payments Totaling $1.1 Million

• 05:55 AM ET Jul 23, 2025
  

  (RDHL) Investment Analysis and Advice

• 03:38 PM ET Jul 21, 2025
  

  RedHill Receives Positive FDA Feedback on Pathway to Approval of Groundbreaking RHB-204 for Crohn's Disease

• 09:03 AM ET Jul 21, 2025
  

  RedHill Biopharma receives positive FDA feedback on pathway to approval of RHB-204 for Crohn's disease ($1.86, 0.00)